SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma clears legal hurdle to launch generic version of Copaxone

21 Apr 2014 Evaluate

The US Supreme Court Chief Justice Roberts has denied Teva’s application for an injunction seeking to prevent launch of a generic version of Copaxone pending the Supreme Court’s decision on Teva’s appeal. This has cleared legal hurdle for Mylan & Natco Pharma to launch the same at market formation. This is the second time that the Chief Justice has denied Teva’s request for such an injunction.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

1208.75 34.75 (2.96%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×